Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006

Bulletin du Cancer

Volumn 96, Issue 4, 2009, Pages

  Seradour B ^a   Allemand, H ^b   Weill, A ^b   Ricordeau, P ^b  

^a Arcades (Assoc Pour la Rech et le Depistage des Cancers du Sein   (France)

^b Caisse Nationale d'Assurance Maladie des Travailleurs Salaries   (France)

Author keywords

Breast cancer; France; Hormone replacement therapy; Incidence; Screening

Indexed keywords

ESTROGEN; PROGESTERONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER SCREENING; FEMALE; FRANCE; GROUPS BY AGE; HEALTH PROGRAM; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; OUTCOME ASSESSMENT; PRESCRIPTION; PREVALENCE;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; FRANCE; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; MAMMOGRAPHY; MIDDLE AGED; NATIONAL HEALTH PROGRAMS;

EID: 66449083853     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0869     Document Type: Article

References (23)

1. Remontet L, Esteve J, Bouvier AM, Grosclaude P, Launoy G, Menegoz F, et al. Cancer incidence and mortality in France over the period 1978-2000. Rev Epidemiol Sante Publique 2003; 51: 3-30.
2. Colonna M, Delafosse P, Uhry Z, Poncet F, Arveux P, Molinie F, et al. Is breast cancer incidence increasing among young women? An analysis of the trend in France for the period 1983-2002. Breast 2008; 17: 289-292
3. Allemand H, Séradour B, Weill A, Ricordeau P. Decline in breast cancer incidence in 2005 and 2006 in France: a paradoxical trend. Bull Cancer 2008; 95 (1): 11-15
4. Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, et al. The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 2007; 356: 1670-1674
5. Canfell K, Banks E, Moa AM, Beral V. Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 2008; 188: 641-644
6. Katalanic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008; 107: 427-430
7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomize controlled trial. JAMA 2002; 288: 321-333 (Pubitemid 34761611)
8. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009; 360: 573-587
9. Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ, et al. Recent decline in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol 2006; 24 (33): e49-50.
10. Robbins A, Clarke C. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 2007; 25: 3437-3439
11. Gorza M, Salines E, Bloch J. 2009 Breast cancer screening programme in France - Results 2005. Saint-Maurice (Fra): Institut de veille sanitaire, décembre 2008, 366 p (5 février 2009) www.invs.sante.fr.
12. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among US women. Breast Cancer Res 2007; 9: R28. (Pubitemid 350214681)
13. Glass AG, Lacey JV, Carreon JD. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007; 99: 1152-1161
14. Surveillance, Epidemiology and End Results Program home page (accessed January 12, 2009, at http:/seer.cancer.gov/.).
15. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360 (9337): 742-944. (Pubitemid 35283842)
16. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 2008; 107 (1): 103-111 (Pubitemid 350179584)
17. Dietel M, Lewis MA, Shapiro S. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 2005; 20 (8): 2052-2060 (Pubitemid 41418488)
18. Czernichow C, This P, Asselain B, Falcou MC, Savignoni A, Salmon RJ, et al. HRT in postmenopausal women and breast cancer in the Institute-Curie. Bull Cancer 2007; 94 (5): 469-475 (Pubitemid 46981010)
19. Carney P, Miglioretti D, Yankaskas B. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003; 138: 168-175 (Pubitemid 36231622)
20. Séradour B, Estève J, Heid P, Jacquemier J. Hormone replacement therapy and screening mammography: analysis of the results in the Bouches-du-Rhône programme. J Med Screen 1999; 6: 99-102. (Pubitemid 29320847)
21. Verkooijen HM, Koot V, Fioretta G. Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations. Breast Cancer Res Treat 2007; 107: 389-395
22. French Health Products Safety Agency (Afssaps). Report on hormonal replacement therapy for menopause. 2005.
23. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005; 114: 448-454 (Pubitemid 40279968)